Background
The menace caused by viral infections to the health of the public cannot be overstated. Particularly, the frequent outbreaks of newly emerging and re-emerging viruses (from endemic to pandemic situations) coupled with the lack of or limited availability of antiviral drugs and vaccines against them, poses a threat to human survival socio-economically, as evident in the current COVID-19 pandemic [
29,
39]. More so, for some viral infections, there is fast development of drug-resistant viral strains due mutation especially, RNA viruses (lacking proof-read mechanisms), and limitation of vaccine use in immunocompromised individuals [
28].These have highlighted the need for antiviral drug discovery.
Enteroviruses are non-enveloped icosahedra virion with single-stranded positive sense RNA genome of 7.5 kb size. They belong to 13 species of genus
Enterovirus in the picornaviridae family, four (EV-A to D) of which have been found to constantly infect humans [
9]. Clinical manifestations include aseptic meningitis, neonatal sepsis, myocarditis, type 1 diabetes, hand-foot-and-mouth disease, and acute flaccid paralysis. Poliovirus, the aetiological agent of poliomyelitis is a typical member of enterovirus species C alongside Coxsackievirus A13 (CV-A13), CV-A20, Enterovirus C99 (EV-C99) and others [
7,
20].
In Nigeria, circulating vaccine-derived polioviruses (cVDPVs) have been implicated to result from recombination of non-polio enterovirus species C (NPESC) members particularly CV-A13, CV-A20, CV-A11, and CV-A17 with oral polio vaccine (OPV) [
1]. The International Health Regulations (IHR) classified Nigeria as a state infected with cVDPVs with potential risk of international spread [
12]. Yet, there is currently no available antiviral drugs approved for enterovirus infections.
Peptides, for therapeutic considerations have been faced with concern and limitations such as poor pharmacokinetic properties, and high molecular weight (immunogenicity) [
17,
23,
24,
31,
45]. Some techniques such as cyclization, incorporation of unnatural amino acids, recombinant techniques have been employed to enhance properties of target peptides [
17]. Diverse peptides are produced by plants for various metabolic purposes including defence against attacks from microbes, herbivores and pests [
8]. As plants continue to be a veritable source for drug discovery, the presence of cysteine-rich peptides including the circular variants in plants and particularly, cysteine-rich circular peptides known as cyclotides, brightens the future of peptide drug discovery. Of the five structural groups of antimicrobial plant peptides [
18], cyclotides are found to be ultra-stable, being able to withstand extreme conditions of temperature, chemical, and enzymatic treatment [
2,
16].
Viral therapeutic peptides are emerging [
11], yet plant-derived peptides have not been explored for antiviral activity. Herein, we evaluated the antiviral effect of partially-purified peptide fraction (P-PPf) from seven medicinal plants belonging to Rubiaceae, Euphorbiaceae, Phyllantaceae, and Apocynaceae families against 3 members of NPESC.
Methods
Plants material collection, authentication and peptide extraction
Leaf part of 3 plants from Euphorbiaceae, 1 from Rubiaceae, 1 from Phyllantaceae and 2 from Apocynaceae were collected from the Botanical Garden of [BLINDED FOR PEER REVIEW], identified and authenticated at Forestry Herbarium Ibadan (FHI). Leaves were air-dried, pulverized and subjected to aqueous and then solid-phase extractions. Extraction method was employed in view of cyclotides, using previously described procedures [
8,
14‐
16]. Briefly, plants leaves were subjected to aqueous extraction by maceration in dichloromethane/methanol (1:1; v/v) for 24 h at 25 °C with continuous agitation. After 24 h, water was added to obtain aqueous-rich fraction. The concentrated aqueous-rich fraction was further subjected to reverse-phase solid-phase extraction (RP-SPE) using C
18 columns (Phenomenex, Aschaffenburg, Germany) and eluted with solvent B (90% (v/v) acetonitrile, 0.045% (v/v) trifluoroacetic acid in double distilled water). Hydrophilic compounds were separated from partially purified peptide fraction (P-PPf) by eluting with 20% and 80% solvent B, respectively. The P-PPfs were freeze-dried and stored in the refrigerator at 4 °C until used for bioassay.
Thin layer chromatography (TLC) chemical detection of peptides
A modified method previously described by WenYan et al
. [
48] and Attah et al
. [
2] was adopted for the TLC chemical detection. Pre-coated TLC plates (G
254 MERCK, Germany) and solvent system
n-butanol:acetic acid:water (3:1:1) were used. Each solvent-dissolved peptide extract was spotted on the TLC plate and developed in the solvent system above. Plates were allowed to dry, viewed under UV at 254 and 365 nm. Dried plates (TLC chromatograms) were swiftly sprayed or dipped in freshly prepared G-250 modified stain or ninhydrin, respectively.
For antiviral screening, 20 mg of fractions (crude and peptide-rich) was each dissolved in 2 mL dimethylsulfxoide (DMSO) to obtain stock solutions (10 mg/mL).
Cell and virus
Human breast adenocarcinoma cancer cell line (MCF-7) obtained from WHO national Polio Lab, Ibadan, Nigeria was used for both cytotoxic and antiviral studies. Cells were grown in Eagle’s minimum essential medium (MEM) supplemented with 10% foetal bovine serum (FBS), 100 units/mL of penicillin, 100 μg/mL of streptomycin, 2 mM L-glutamine, 0.07% NaHCO3, 1% non-essential amino acids and vitamin solution at 37 °C in a humidify incubator (85–95% humidity). Three species C enterovirus members, including two serotypes of coxsackie virus A (CV-A13 and CV-A20) and a numbered Enterovirus C serotype (EV-C99) were obtained from stool isolates [
9] by the Enterovirus research group, Department of Virology, [BLINDED FOR PEER REVIEW]. The test medium used for cytotoxic assays and antiviral assays contained only 2% FBS.
Preparation of viral stocks
To increase the quantity of virion stocks, virus suspension (200 µL) was inoculated into the T25 flask of cultured MCF-7 cells, and incubated at 37 °C for about 72 h for 100% cytopathic effect. Afterwards, medium was centrifuged and aliquots of supernatant were made into cryovials. All viral stocks were stored at − 70 °C until use.
Tissue culture infective dose (TCID50)
Virus titre was determined by virus-induced cytopathic effect (vCPE) in MCF-7 cell and were expressed as 50% tissue culture infective concentration (TCID50) per mL. Briefly, 100 µL MCF-7 cell suspension (1 × 105 cells/mL) was seeded into a 96-well microtitre plate and incubated for 24 h to form monolayer. Afterward, virus suspension (100 µL) was inoculated into the eight wells (as replicates) of each column 1–10 with varying (ten-fold serially diluted- 10–1 to 10–10) concentration per column. Column 11 and 12 served as the cell control. Plate was incubated at 37 °C, and daily CPE scoring was done for about 7 days when cell control wells started dying off. The TCID50 values were determined using Spearman–Karber’s method and 100 TCID50 was used for the antiviral assay.
Cytotoxicity assay
The maximum nontoxic concentration (MNTC) test of crude fractions to MCF-7 cells in culture was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich®) assay, a colorimetric assay that reliably measures cell viability.
Previously described method by Mossmann [
32] was adopted. Briefly, previously seeded monolayers of MCF-7 cells in a 96-well microtitre plate was treated with six serial ten-fold dilutions (1000 to 0.01 μg/mL) of stock solutions of crude and peptide-rich fractions in maintenance medium (2% MEM) for 72 h. Afterwards, plates were observed for MNTC on the cells under an inverted microscope (OLYMPUS CKX31). Afterward, old medium was removed and 25 μL of prepared MTT reagent in phosphate buffer saline (PBS) (2 mg/mL) was added to each well, including controls and plate returned to the incubator for 2 h. Then, DMSO (75 μL) was added to solubilize the formazan crystals formed. Optical density values were obtained by spectrophotometry (Multiscan 347, MTX lab) at 490 nm. Data obtained was used to determine 50% cytotoxic concentration (CC
50).
Virus-induced cytopathic effect (vCPE) reduction assay
Previously described neutralization method [
27,
40] was employed to evaluate the antiviral vCPE inhibition effects of pre-purified peptide fractions on the three species C enteroviruses. Concisely, six serial two-fold dilutions made from the MNTC of each of the fractions was added to confluent cell monolayers in a 96-well plate, and allowed to adsorb for about 1 h at 37 °C, after which 100 TCID
50 virus suspension was added. Plates were incubated at 37 °C for 72 h (plant fractions were kept during incubation). Positive control (virus control) wells were infected with the same concentration of virus but untreated with fractions, while negative (cell control) wells contained only maintenance medium (uninfected and untreated cell). Plates was observed preliminarily under the microscope for vCPE. Thereafter, MTT colorimetric measure was employed as described earlier. The concentration that reduced 50% of CPE with respect to the virus control was defined as the 50% inhibitory concentration (IC
50). Since there are no approved antiviral drugs for enterovirus infections, no standard drug was used.
Data analysis
Selective index, CC50 and IC50
The 50% cytotoxic concentration (CC50) and the 50% inhibitory concentration (IC50) for each extract was calculated from non-linear regression analysis using GraphPad prism5. The selective index, which is the index of safety margin is defined as CC50 over IC50.
Discussion
Historically, medicinal plants have been a valuable source for drug discovery. Plant peptides are gaining attention for drug discovery exploration especially, cysteine-rich circular peptides due to their stability [
3,
11,
50]. Antimicrobial function of plant peptides in plant innate immunity can be explored for antiviral drug discovery [
3,
16]. Though poliovirus infection is on the edge of eradication, there is need to search for antivirals against nonpolio enteroviruses that can substitute the niche as the leading cause of paralysis in children [
5].
In this study, all tested pre-purified peptide fractions from the
Euphorbia species notably showed antiviral effect across all the NPESC serotypes.
Euphorbia hirta evidently showed best activity with IC
50 (≤ 2 µg/mL) and high index of safety margins (SI ≥ 81). Members of Euphorbiaceae family especially,
Euphorbia species extract have been demonstrated for in vitro antiviral activity against RNA and DNA viruses [
10,
13,
21,
22,
25,
37,
38,
40,
42,
44,
51]. Also, various in vitro antiviral activities against hepatitis B, herpes simplex virus, influenza viruses, rhinovirus, and enterovirus [
4,
6,
30,
33,
43,
46] have been displayed by some small molecules from
Euphorbia. Thus, this finding is consistent with reports on antiviral potentials of
Euphorbia species. Among the three
Euphorbia species tested,
E. hirta was observed to show best antiviral activity across the three NPESC serotypes with its p-PPf exerting highly selective antiviral activity, more enhanced than its crude fraction; which is further evident in the relatively higher selective index values of P-PPf of
E. hirta (Table
2).
E. hirta has been documented in ethnomedicine use against infections including viral infections in Philippines, India, Pakistan and Sri Lanka [
41]. Similar peptides with varying proportion or varying peptide constituents in the tested
Euphorbia species could be responsible for their unequal antiviral activity. Ongoing process of isolation and characterization of the peptides will reveal this clearly.
Partially purified peptide fractions from
Allamanda blanchetii showed moderate antiviral effect only on CV-A13 while
Allamanda cathartica lacked antiviral effect only on CV-A13. This varying antiviral effects of the two
Allamanda species observed across the three NPESC serotypes could suggest disparate peptide constituents in the two species. Nguyen and his group reported the presence of allotides, proline-rich cystine knot α-amylase inhibitors from
Allamanda cathartica; the extremely stable disulphide-rich peptides with alpha amylase activity and poor antimicrobial activity [
36].
The antiviral assay design was prophylactic and not therapeutic. Thus, possible mechanism of antiviral action could be the prevention of virus attachment/entry into susceptible MCF-7 cell line used or inhibition of a replication stage that is downstream of entry or direct effect on virion (virucidal). CV-A13 and CV-A20 use cell surface receptor intercellular adhesion molecule 1 (ICAM-1) for entry into susceptible cells [
19], thus binding of peptides to the glycoprotein ICAM-1 is a possible antiviral target. However, alternate cell entry have been documented for CV-A20 other than ICAM-1 [
34], indicating the differing results for some partially purified peptides exhibiting antiviral activity on CV-A13 and not on CV-A20. Plant-derived cysteine knot peptides include alpha amylase inhibitors, cyclotides, thionins, and defensins whose bioactivities lead to blocking of viral infection by clustering the viral particles and blocking receptor binding [
35,
47]. These disulphide stabilised peptides mediate in the inhibition of viral entry, viral particle disruption, interference with essential cell signalling or viral gene expression [
26], or by other poorly-understood mechanisms. In addition to the antiviral activities, cysteine-rich peptides such as defensins modulate adaptive immune responses via mobilization of dendritic cells, induction of their maturation, enhancement of antigen uptake, and mobilization of T Lymphocytes (CD4 + and CD8 + effector T cells) to sites of infection, due to the T cell-chemoattracting effect of defensins [
47,
49].
Conclusion
Semi-purified cysteine-rich peptides in the tested Euphorbia species displayed notable antiviral activity against non-polio enterovirus species C; CV-A13, CV-A20 and EV-C99 in MCF-7 cell culture system. To the best of our knowledge, this is the first antiviral report on semi-purified peptides from the tested plant species and therefore provides scientific rationale for a more extensive study of the individual peptides, molecular targets, safety and efficacy as potential peptide-based therapeutics.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.